Cargando…

Efficacy and Tolerability of Aripiprazole: A 26-Week Switching Study from Oral Antipsychotics

OBJECTIVE: To determine if the maintenance effectiveness and tolerability of aripiprazole demonstrated in a 12-week study were maintained in an extension phase (up to 26 weeks). METHODS: This study was the extension of our switching study from other antipsychotics to aripiprazole in symptomatically...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Jung-Sun, Chung, Seockhoon, Lee, Joon-Noh, Kwon, Jun Soo, Kim, Do Hoon, Kim, Chul Eung, Oh, Kang Seob, Jeon, Yang-Whan, Lee, Min-Soo, Lim, Myung Ho, Chang, Hye-Ryein, Kim, Chang Yoon
Formato: Texto
Lenguaje:English
Publicado: Korean Neuropsychiatric Association 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2947806/
https://www.ncbi.nlm.nih.gov/pubmed/20927307
http://dx.doi.org/10.4306/pi.2010.7.3.189
_version_ 1782187398159925248
author Lee, Jung-Sun
Chung, Seockhoon
Lee, Joon-Noh
Kwon, Jun Soo
Kim, Do Hoon
Kim, Chul Eung
Oh, Kang Seob
Jeon, Yang-Whan
Lee, Min-Soo
Lim, Myung Ho
Chang, Hye-Ryein
Kim, Chang Yoon
author_facet Lee, Jung-Sun
Chung, Seockhoon
Lee, Joon-Noh
Kwon, Jun Soo
Kim, Do Hoon
Kim, Chul Eung
Oh, Kang Seob
Jeon, Yang-Whan
Lee, Min-Soo
Lim, Myung Ho
Chang, Hye-Ryein
Kim, Chang Yoon
author_sort Lee, Jung-Sun
collection PubMed
description OBJECTIVE: To determine if the maintenance effectiveness and tolerability of aripiprazole demonstrated in a 12-week study were maintained in an extension phase (up to 26 weeks). METHODS: This study was the extension of our switching study from other antipsychotics to aripiprazole in symptomatically stable patients with schizophrenia or schizoaffective disorder. All the patients were randomly assigned to the aripiprazole group or the non-aripiprazole group. The effectiveness analysis consisted of the comparison of the upper bound of the 95% confidence interval (CI) of the mean Clinical Global Impression-Improvement (CGI-I) score to 4 (no change) at the end of the study. RESULTS: At the baseline, the aripiprazole group (n=135) and the non-aripiprazole group (n=31) were comparable with respect to their mean ages, gender distribution, baseline Positive and Negative Syndrome Scale scores, and Clinical Global Impression-Severity (CGI-S) scores. The study showed that the mean CGI-I score was 2.92 (95% CI: 2.72-3.12) in the aripiprazole group and 2.81 (95% CI: 2.35-3.26) in the non-aripiprazole group at 26 weeks. In the aripiprazole group, the remission rates at 12 and 26 weeks were 74.8% and 72.6%, respectively, and 80.2% of the patients with remission at 12 weeks maintained their remission state until the end of the study. About one-fourth of the patients in the aripiprazole group reported one or more spontaneous treatment-emergent adverse events, such as insomnia, headache, and nausea. CONCLUSION: This study suggested that most clinically stable outpatients with schizophrenia maintain their remission states after being switched to aripiprazole, without serious symptom aggravation and adverse events over a course of 26 weeks.
format Text
id pubmed-2947806
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Korean Neuropsychiatric Association
record_format MEDLINE/PubMed
spelling pubmed-29478062010-10-06 Efficacy and Tolerability of Aripiprazole: A 26-Week Switching Study from Oral Antipsychotics Lee, Jung-Sun Chung, Seockhoon Lee, Joon-Noh Kwon, Jun Soo Kim, Do Hoon Kim, Chul Eung Oh, Kang Seob Jeon, Yang-Whan Lee, Min-Soo Lim, Myung Ho Chang, Hye-Ryein Kim, Chang Yoon Psychiatry Investig Original Article OBJECTIVE: To determine if the maintenance effectiveness and tolerability of aripiprazole demonstrated in a 12-week study were maintained in an extension phase (up to 26 weeks). METHODS: This study was the extension of our switching study from other antipsychotics to aripiprazole in symptomatically stable patients with schizophrenia or schizoaffective disorder. All the patients were randomly assigned to the aripiprazole group or the non-aripiprazole group. The effectiveness analysis consisted of the comparison of the upper bound of the 95% confidence interval (CI) of the mean Clinical Global Impression-Improvement (CGI-I) score to 4 (no change) at the end of the study. RESULTS: At the baseline, the aripiprazole group (n=135) and the non-aripiprazole group (n=31) were comparable with respect to their mean ages, gender distribution, baseline Positive and Negative Syndrome Scale scores, and Clinical Global Impression-Severity (CGI-S) scores. The study showed that the mean CGI-I score was 2.92 (95% CI: 2.72-3.12) in the aripiprazole group and 2.81 (95% CI: 2.35-3.26) in the non-aripiprazole group at 26 weeks. In the aripiprazole group, the remission rates at 12 and 26 weeks were 74.8% and 72.6%, respectively, and 80.2% of the patients with remission at 12 weeks maintained their remission state until the end of the study. About one-fourth of the patients in the aripiprazole group reported one or more spontaneous treatment-emergent adverse events, such as insomnia, headache, and nausea. CONCLUSION: This study suggested that most clinically stable outpatients with schizophrenia maintain their remission states after being switched to aripiprazole, without serious symptom aggravation and adverse events over a course of 26 weeks. Korean Neuropsychiatric Association 2010-09 2010-07-09 /pmc/articles/PMC2947806/ /pubmed/20927307 http://dx.doi.org/10.4306/pi.2010.7.3.189 Text en Copyright © 2010 Korean Neuropsychiatric Association http://creativecommons.org/licenses/by-nc/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Lee, Jung-Sun
Chung, Seockhoon
Lee, Joon-Noh
Kwon, Jun Soo
Kim, Do Hoon
Kim, Chul Eung
Oh, Kang Seob
Jeon, Yang-Whan
Lee, Min-Soo
Lim, Myung Ho
Chang, Hye-Ryein
Kim, Chang Yoon
Efficacy and Tolerability of Aripiprazole: A 26-Week Switching Study from Oral Antipsychotics
title Efficacy and Tolerability of Aripiprazole: A 26-Week Switching Study from Oral Antipsychotics
title_full Efficacy and Tolerability of Aripiprazole: A 26-Week Switching Study from Oral Antipsychotics
title_fullStr Efficacy and Tolerability of Aripiprazole: A 26-Week Switching Study from Oral Antipsychotics
title_full_unstemmed Efficacy and Tolerability of Aripiprazole: A 26-Week Switching Study from Oral Antipsychotics
title_short Efficacy and Tolerability of Aripiprazole: A 26-Week Switching Study from Oral Antipsychotics
title_sort efficacy and tolerability of aripiprazole: a 26-week switching study from oral antipsychotics
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2947806/
https://www.ncbi.nlm.nih.gov/pubmed/20927307
http://dx.doi.org/10.4306/pi.2010.7.3.189
work_keys_str_mv AT leejungsun efficacyandtolerabilityofaripiprazolea26weekswitchingstudyfromoralantipsychotics
AT chungseockhoon efficacyandtolerabilityofaripiprazolea26weekswitchingstudyfromoralantipsychotics
AT leejoonnoh efficacyandtolerabilityofaripiprazolea26weekswitchingstudyfromoralantipsychotics
AT kwonjunsoo efficacyandtolerabilityofaripiprazolea26weekswitchingstudyfromoralantipsychotics
AT kimdohoon efficacyandtolerabilityofaripiprazolea26weekswitchingstudyfromoralantipsychotics
AT kimchuleung efficacyandtolerabilityofaripiprazolea26weekswitchingstudyfromoralantipsychotics
AT ohkangseob efficacyandtolerabilityofaripiprazolea26weekswitchingstudyfromoralantipsychotics
AT jeonyangwhan efficacyandtolerabilityofaripiprazolea26weekswitchingstudyfromoralantipsychotics
AT leeminsoo efficacyandtolerabilityofaripiprazolea26weekswitchingstudyfromoralantipsychotics
AT limmyungho efficacyandtolerabilityofaripiprazolea26weekswitchingstudyfromoralantipsychotics
AT changhyeryein efficacyandtolerabilityofaripiprazolea26weekswitchingstudyfromoralantipsychotics
AT kimchangyoon efficacyandtolerabilityofaripiprazolea26weekswitchingstudyfromoralantipsychotics